Nutrition BioTech posts NMN buyer guide tied to FDA records
Nutrition BioTech has published a buyer guide for bulk NMN powder that connects 2025 FDA records with the documents supplement brands should request from suppliers. The guide is aimed at helping U.S. buyers verify regulatory support, quality records and inventory details before placing orders.
Why it matters: - Bulk NMN buyers are under pressure to verify both regulatory footing and supplier documentation before sourcing ingredient lots. - Nutrition BioTech’s guide is meant to help brands connect FDA records with the documents they should request from a manufacturer or supplier. - The guide points buyers to source documents that can inform purchasing decisions for bulk NMN powder in the U.S. market.
What happened: - Nutrition BioTech, also known as NaturalBestBio, published a buyer guide on bulk NMN powder and 2025 FDA records. - The guide includes links to original FDA documents and is positioned for supplement brands evaluating bulk NMN suppliers. - The company is based in Pomona, California, and sells nutraceutical ingredients to B2B buyers.
The details: - FDA said in a Sept. 29, 2025 response to a citizen petition that NMN is not excluded from the dietary supplement definition under the drug-preclusion provision discussed in that response. - FDA issued follow-up letters on individual NMN notifications on Dec. 2, 2025. - FDA described acceptance of a notification for filing as procedural. - The guide says the 2025 records do not prove that every supplier’s material or finished product meets all applicable requirements. - Buyers still need to confirm the regulatory basis a supplier relies on and match it to the ingredient, the submitting entity and the intended conditions of use. - The guide tells buyers to request a lot certificate of analysis, specification sheet and safety data sheet. - The guide also calls for heavy-metal and microbiology results with methods, quality-system certificates and scope, allergen, non-GMO and BSE/TSE statements, and a country-of-origin statement. - Buyers are also told to request the complete FDA notification correspondence, or a documented basis for no notification. - Packaging, storage and stability documentation are also listed as requested records. - Nutrition BioTech’s NMN product is β-Nicotinamide mononucleotide powder, CAS 1094-61-7. - The product specification is NLT 99.0% by HPLC. - The company says it holds ready stock in the United States. - Minimum order is 1 kg. - Packaging is 25 kg per drum, with smaller quantities available. - Dispatch is listed as within 3 working days of purchase order. - Production capacity is listed at 10 tonnes per month. - Shelf life is three years. - The quality system includes ISO 22000:2018, FSSC 22000 and HACCP, with certificates available on request. - Nutrition BioTech says an NDI notification for the NMN it supplies has been submitted to FDA, and notification documents are available to qualified buyers on request. - The company links the buyer guide here: Buyer guide to the 2025 FDA NMN records. - The company also links NMN specifications and sample requests here: NMN specifications and sample requests.
Between the lines: - The release is aimed at buyers who want a paper trail, not just a product spec sheet. - By emphasizing FDA correspondence, the company is signaling that documentation has become a key part of NMN sourcing decisions. - The focus on ready U.S. stock, minimum order size and rapid dispatch suggests the guide is tied to commercial procurement as much as regulatory review.
What's next: - Buyers using NMN in supplements are likely to keep asking for FDA-related records, test data and quality-system evidence before placing orders. - Nutrition BioTech says qualified buyers can request notification documents, which could become part of its sales process. - The guide may serve as a reference point for other NMN suppliers competing on documentation and supply-chain readiness.
The bottom line: - Nutrition BioTech is packaging its NMN supply offer with a regulatory-documentation guide, betting that FDA records and quality proofs matter as much as price and inventory.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
California Health Watch
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.